AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12728215
Drug: Formulated soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated soy stanols (1.9 g) in a lemonade-flavored beverage
Trial: 12728215
Drug: Formulated soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated soy stanols (1.9 g) in egg whites
Trial: 1637574
Drug: Intravenous salcatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous salcatonin (100 U/d, continuous infusion for five days)
Trial: 1637574
Drug: Intramuscular salcatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular salcatonin (100 U/d, single bolus for five days)
Trial: 6425913
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg d‐amphetamine
Trial: 6425913
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of d‐amphetamine
Trial: 20436049
Drug: Non-compliance with
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-compliance with daily weighing
Trial: 11932310
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment for 7 days
Trial: 11932310
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment for 12 months
Trial: 2122026
Drug: ILB method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILB method (gentamicin mixed using total nutrient admixture solution)
Trial: 26217065
Drug: BMAC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BMAC infusion in NIHF group
Trial: 26217065
Drug: BMAC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BMAC infusion in IHF group
Trial: 17142929
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral treatment with 5 mg of folate and 1,500 microg of mecobalamin
Trial: 12798401
Drug: Screening by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening by oral visual inspection by trained health workers at 3-year intervals
Trial: 1607550
Drug: Intranasal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal triamcinolone acetonide aerosol (ITAA) 220 micrograms/day
Trial: 1607550
Drug: Intranasal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal triamcinolone acetonide aerosol (ITAA) 440 micrograms/day
Trial: 6382361
Drug: Moclobemide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (mean daily dose 297 mg, treatment duration 2-4 weeks)
Trial: 29350840
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate sinus implants
Trial: 27907074
Drug: Group-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based acceptance and commitment therapy (ACT)
Trial: 24393423
Drug: Step count
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step count prescription with pedometers, aiming to increase counts by ≥3,000 steps/day over one year, with individualized rate increase.
Trial: 22081474
Drug: Scheduled infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Scheduled infliximab (IFX) at 5 mg/kg intravenously every 8 weeks for 36 months
Trial: 20613538
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy (groups 2 and 3) aiming to maintain the pulse contour-derived cardiac index above 2.5 l m min.
Trial: 17992069
Drug: Health diary
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health diary program (50 minutes, twice a week for 8 weeks)
Trial: 11806971
Drug: 200 mg/m(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m(2) melphalan (arm B)
Trial: 11806971
Drug: 8 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 Gy total body irradiation plus 140 mg/m(2) melphalan (arm A)
Trial: 7857101
Drug: 5'‐DFUR (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR (daily dose 800 mg for 3 days)
Trial: 7857101
Drug: UFT (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (daily dose 600 mg for 3 days)
Trial: 1719736
Drug: 10% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydroxyethyl starch solution (HAES 200/0.62)
Trial: 1719736
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch solution (HES 200.000/0.62)
Trial: 30673866
Drug: Fludroxycortide cream
RxNorm normalized name: fludroxycortide
DrugBank: Flurandrenolide (DB00846)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure.
Trial: 30673866
Drug: Fludroxycortide cream
RxNorm normalized name: fludroxycortide
DrugBank: Flurandrenolide (DB00846)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks.
Trial: 21185503
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and 80 mg
Trial: 21185503
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (not specified treatment)
Trial: 19552619
Drug: Linagliptin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (10 mg/day)
Trial: 19552619
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg three times daily)
Trial: 19552619
Drug: Linagliptin and
RxNorm normalized name: linagliptin and empagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin co-administration
Trial: 15025737
Drug: Cetirizine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine administered orally in various formulations and in single and multiple dosage regimens
Trial: 11965201
Drug: Rofecoxib (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (average 24.7 mg daily)
Trial: 11965201
Drug: NSAIDs (ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (ibuprofen 800 mg thrice daily, diclofenac 50 mg thrice daily, nabumetone 1500 mg daily)
Trial: 10023325
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion cisplatin (arm B)
Trial: 25664387
Drug: Reduced substance
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced substance use (drugs)
Trial: 25664387
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to additional treatment modalities
Trial: 25664387
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to prescribed medication
Trial: 18556609
Drug: Randomized encouragement
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized encouragement designs where participants are randomly invited to participate in treatment conditions but can choose whether to receive treatment.
Trial: 18556609
Drug: Quantitative assignment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative assignment designs where treatment is assigned based on a quantitative measure (e.g., need, merit, risk).
Trial: 18556609
Drug: Observational studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational studies where treatment assignment is unknown and presumed to be nonrandom.
Trial: 16778647
Drug: Latanoprost therapy
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost therapy for 1 month
Trial: 16778647
Drug: Brimonidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine treatment for nonresponders
Trial: 16778647
Drug: Timolol treatment
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol treatment for nonresponders
Trial: 16778647
Drug: Pilocarpine treatment
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine treatment for nonresponders
Trial: 12970829
Drug: Therapy-based studies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy-based studies
Trial: 12970829
Drug: Drug-based studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-based studies
Trial: 11573055
Drug: GRF glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF glue as a topical haemostatic agent
Trial: 9572319
Drug: Antisecretory drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory drugs in H. pylori-positive peptic ulcer patients taking NSAIDs
Trial: 7875101
Drug: Transvaginal intra-amniotic
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal intra-amniotic injection of methotrexate (MTX, 100 mg)
Trial: 2851173
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course)
Trial: 2851173
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course) plus lonidamine (LND)
Trial: 2851173
Drug: Chemotherapy/radiation (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/radiation (arm A)
Trial: 2851173
Drug: Chemotherapy/radiation/LND (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/radiation/LND (arm B)
Trial: 2851173
Drug: Chemotherapy/radiation/LND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/radiation/LND
Trial: 30553135
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management (intentional early delivery 24 hours after second steroid dose)
Trial: 23919808
Drug: Multi-component physical
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component physical activity intervention including indoor physical activity, recess, daily lessons, and social environment
Trial: 21195573
Drug: Indapamide 1.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.5mg sustained release and 2.5mg immediate release formulations
Trial: 14616224
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase or augmentation with lithium or desipramine
Trial: 9772437
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg orally q12h for 2 days followed by misoprostol 25 micrograms intravaginally q12h
Trial: 9772437
Drug: Sodium prasterone
RxNorm normalized name: prasterone sodium sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium prasterone sulfate 200 mg intravenously qd for 3 days followed by oxytocin intravenous infusion
Trial: 8380487
Drug: Milacemide (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide (1,200 mg, single oral dose)
Trial: 31290990
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) - 14 RCTs (1 ipilimumab, 5 pembrolizumab, 5 nivolumab, 2 atezolizumab, 1 durvalumab)
Trial: 31290990
Drug: Non-immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immune checkpoint inhibitors - 86 RCTs (74 targeted therapy, 8 chemotherapy, 3 hormone therapy, 1 radiopharmaceutical)
Trial: 31290990
Drug: Non-immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immune checkpoint inhibitors
Trial: 26556079
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (including methylphenidate)
Trial: 26556079
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drug therapy and perceptual motor training
Trial: 16185211
Drug: Methadone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 50 mg
Trial: 16185211
Drug: Methadone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 100 mg
Trial: 16185211
Drug: Methadone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 150 mg
Trial: 14621086
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 microg pressurised metered dose inhaler
Trial: 10376691
Drug: Lindane (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindane (1% topical application)
Trial: 1839379
Drug: TAP-144-SR (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP-144-SR (all doses)
Trial: 1839379
Drug: TAP-144-SR (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP-144-SR (doses >30 micrograms/kg)
Trial: 27415850
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) consisting of 8 telephone sessions, a patient education book, and a stress management procedure on compact disc.
Trial: 14527931
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus injection of 50 microm/m2 of G‐CSF (SI)
Trial: 14527931
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous injection of 50 microm/m2 of G‐CSF for 24 h (CI)
Trial: 21777897
Drug: 3.9 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 g/d tranexamic acid
Trial: 21777897
Drug: 1.95 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.95 g/d tranexamic acid
Trial: 19459424
Drug: Ingavirin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingavirin (90 mg once daily for 5 days)
Trial: 19459424
Drug: Arbidol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbidol (200 mg 4 times a day for 5 days)
Trial: 14713135
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/d) plus contingency management
Trial: 14713135
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/d) plus noncontingent voucher control
Trial: 10890475
Drug: Hemofiltration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Trial: 10890475
Drug: Hemofiltration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Trial: 10890475
Drug: No hemofiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hemofiltration with half‐Hammersmith dosing regimen of aprotinin
Trial: 10890475
Drug: No hemofiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hemofiltration with full‐Hammersmith dosing regimen of aprotinin
Trial: 8851621
Drug: Ceftriaxone 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia (group 1)
Trial: 8851621
Drug: Ceftriaxone 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1,000 mg intravenously followed by a second 1,000 mg at initiation of cardiopulmonary bypass (group 2)
Trial: 6422868
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain enriched therapy at 0.7 gm/kg/day of branched chain amino acids
Trial: 6422868
Drug: Balanced parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced parenteral nutrition with 1.5 gm/kg/day of amino acids, 30 calories/kg/day of glucose, and 7 calories/kg/day of fat
Trial: 20127537
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg i.v. Lornoxicam
Trial: 15481277
Drug: Heavy progressive
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy progressive resistance training (RE) twice a week for 12 weeks
Trial: 9541173
Drug: Night-time continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time continuous subcutaneous insulin infusion (CSII) therapy
Trial: 2656442
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g piracetam/day i.v. followed by 3 x 800 mg/day p.o. for 8 weeks
Trial: 29548719
Drug: Dapagliflozin/metformin XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin/metformin XR FCDP (10/1000 mg)
Trial: 29548719
Drug: Individual component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual component tablets (dapagliflozin [10 mg] plus metformin XR [2 × 500 mg])
Trial: 28895887
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose (HD: high dose)
Trial: 28895887
Drug: 5X/week (MD:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5X/week (MD: Moderate Dose)
Trial: 28895887
Drug: 3X/week (LD:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3X/week (LD: Low Dose)
Trial: 20921029
Drug: Intermittent high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-intensity therapy (Group A): 3 two-month blocks, 4 sessions per week (30-45 minutes each), total 96 sessions
Trial: 20921029
Drug: Continuous low-intensity
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low-intensity therapy (Group B): 2 sessions per week (30-45 minutes each), total 104 sessions
Trial: 20921029
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (Continuous low-intensity therapy)
Trial: 16396977
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg/day)
Trial: 15335093
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate gel
Trial: 15335093
Drug: Neem extract
RxNorm normalized name: neem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neem extract gel
Trial: 11071803
Drug: High-dose lisinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lisinopril (32.5-35 mg/day)
Trial: 11071803
Drug: Low-dose lisinopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lisinopril (2.5-5 mg/day)
Trial: 9186877
Drug: Saline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline and Morphine (N = 12)
Trial: 8084977
Drug: Lithium (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (maintenance therapy)
Trial: 8084977
Drug: Nonpharmacologic approaches
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic approaches (ECT, sleep deprivation, light therapy)
Trial: 24968129
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 20-2 ppm for 24 days
Trial: 24968129
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 2 ppm
Trial: 19144162
Drug: Therapy online
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy online
Trial: 12930486
Drug: Anxiety-blocker (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety-blocker (placebo purported to block anxiety)
Trial: 1665179
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Trial: 1665179
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Trial: 26106632
Drug: Intravenous midazolam‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous midazolam‐ketamine
Trial: 26106632
Drug: Intravenous midazolam‐fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous midazolam‐fentanyl
Trial: 12972723
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment for two months followed by semi-standardized acupuncture (75 patients, waiting list control)
Trial: 10755576
Drug: rhGH (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.05 mg/kg subcutaneously)